The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome

References

• Forastiero R, Martinuzzo M. Antigen specificity and clinical relevance of antiphospholipid syndrome-related autoantibodies. Curr Rheumatol Rev 2005;1:177-87
   Google Scholar
• Keeling D, Mackie I, Moore G, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509
   PubMed Web of Science ®Google Scholar
• Forastiero R, Martinuzzo M, de Larrañaga G. New insights exploring differences Interaction between antiphospholipid syndrome and infections related antiphospholipid antibodies. In: New Research on Autoantibodies. Claude T, Petrelli, editors. Nova Science Publishers, Inc; 2008;5:131-49
   Google Scholar
• de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105:1540-5
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette J, Font J, et al. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019-37
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE: a prospective analysis of 500 consecutive patients. Medicine 1989;68:353-6
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
   PubMed Web of Science ®Google Scholar
• Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost 2012;38:348-52
   PubMed Web of Science ®Google Scholar
• Pengo V, Banzato A, Denas G, et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013;12:832-4
   PubMed Web of Science ®Google Scholar
• Sciascia S, Lopez-Pedrera C, Roccatello D, Cuadrado MJ. Catastrophic antiphospholipid syndrome (CAPS). Best Pract Res Clin Rheumatol 2012;26:535-41
   PubMed Web of Science ®Google Scholar
• Cervera R, Tektonidou M, Espinosa G, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 2011;20:165-73
   PubMed Web of Science ®Google Scholar
• Forastiero R. Bleeding in the antiphospholipid syndrome. Hematology (Am Soc Hematol Educ Program) 2012;17:153-5
   Google Scholar
• Horbach DA, van Oort E, Donders CJM, et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32
   PubMed Web of Science ®Google Scholar
• Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian Registry. Am J Med 1996;100:530-6
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23
   PubMed Web of Science ®Google Scholar
• Martinuzzo M, Forastiero R, Carreras LO. Anti beta2-glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995;89:397-402
   PubMed Web of Science ®Google Scholar
• The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069-73
   PubMed Web of Science ®Google Scholar
• Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997;28:1660-5
   PubMed Web of Science ®Google Scholar
• Amengual O, Atsumi T, Khamashta M, et al. Specificity of ELISA for antibody to beta2-glycoprotein I in patients with antiphospholipid syndrome.Br J Rheumatol. 1996;35:1239-43
   Google Scholar
• Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899-906
   PubMed Web of Science ®Google Scholar
• Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun 2000;15:163-72
   PubMed Web of Science ®Google Scholar
• Galli M. The antiphospholipid triangle. J Thromb Haemost 2010;8:234-6
   PubMed Web of Science ®Google Scholar
• Bertolaccini MA, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014;13:917-30
   PubMed Web of Science ®Google Scholar
• Akter E, Shums Z, Norman G, et al. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol 2013;40:282-6
   PubMed Web of Science ®Google Scholar
• Lopez LR, Santos ME, Espinoza LR, La Rosa FG. Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Pathol 1992;98:449-54
   Web of Science ®Google Scholar
• Weidmann CE, Wallace DJ, Peter JB, et al. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 1988;15:74-9
   PubMed Web of Science ®Google Scholar
• Merkel PA, Chang Y, Pierangeli SS, et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576-83
   PubMed Web of Science ®Google Scholar
• Molina JF, Gutierrez-Urena S, Molina J, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997;24:291-6
   PubMed Web of Science ®Google Scholar
• Diri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and a beta 2 glycoprotein I is the most frequent isotype. Lupus 1999;8:263-8
   PubMed Web of Science ®Google Scholar
• Murthy V, Willis R, Romay-Penabad Z, et al. Value of isolated IgA anti- beta 2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013;65:3186-93
   PubMed Web of Science ®Google Scholar
• Lee SS, Cho ML, JOO YS, et al. Isotypes of anti-beta-2-gycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001;28:520-4
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Atsumi T, Escudero Contreras A, et al. The value of IgA antiphospholipid testing for diagnosis of antiphopholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28:2637-43
   PubMed Web of Science ®Google Scholar
• Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006;33:1775-9
   PubMed Web of Science ®Google Scholar
• Laroche P, Berard M, Rouquette AM, et al. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol 1996;106:549-54
   PubMed Web of Science ®Google Scholar
• Tebo AE, Jaskowski TD, Phansalkar AR, et al. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol 2008;129:870-5
   PubMed Web of Science ®Google Scholar
• Obayashi S, Ozaki Y, Sugi T, et al. Antiphosphatidylethanolamine antibodies might not be an independent risk factor for further miscarriage in patients suffering recurrent pregnancy loss. J Reprod Immunol 2010;85:186-92
   PubMed Web of Science ®Google Scholar
• Sugi T, Katsunuma J, Izumi S, et al. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999;71:1060-5
   PubMed Web of Science ®Google Scholar
• Sanmarco M, Gayet S, Alesi MC, et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007;97:949-54
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Murru V, Sciascia S, et al. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). Thromb Res 2012;130:914-18
   PubMed Web of Science ®Google Scholar
• Matsuda J, Sanaka T, Nishizawa A, et al. Two antiprothrombin antibodies against prothrombin and prothrombin-phosphatidyl serine show partial but not total identity. Blood Coagul Fibrinolysis 2012;13:697-702
   Web of Science ®Google Scholar
• Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007;5:1158-64
   PubMed Web of Science ®Google Scholar
• Sciascia S, Sanna G, Murru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. Thromb Haemost 2014;111:354-64
   PubMed Web of Science ®Google Scholar
• Puurunen M, Vaarala O, Julkunen H, et al. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996;80:16-22
   PubMedGoogle Scholar
• Forastiero RR, Martinuzzo ME, Cerrato GS, et al. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008-14
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Atsumi T, Khamashta M, et al. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998;25:1104-8
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Sciascia S, Murru V, et al. Prevalence of antibodies to prothrombin in solid-phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with or without lupus anticoagulant. Thromb Haemost 2013;109:207-13
   PubMed Web of Science ®Google Scholar
• Vlagea A, Gil A, Cuesta MV, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost 2013;19:289-96
   PubMed Web of Science ®Google Scholar
• de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009;7:1767-73
   PubMed Web of Science ®Google Scholar
• Cousins L, Pericleous C, Khamashta M, et al. Antibodies to domain I of beta -2-glycoprotein I and IgA antiphospholipid antibodies in patients with “seronegative” antiphospholipid syndrome. Ann Rheum Dis 2015;74:317-19
   PubMed Web of Science ®Google Scholar
• Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012;12:313-17
   PubMed Web of Science ®Google Scholar
• Pengo V, Banzato A, Bison E, et al. Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus 2010;19:428-31
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Gresele P, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol 2007;27:309-10
   Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:147-52
   Google Scholar
• Ruffatti A, Tonello M, del Ross T, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006;96:337-41
   PubMed Web of Science ®Google Scholar
• Hernández-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 2013;31:382-8
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-42
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714-18
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics: 2011 update. A report from the American Heart Association. Circulation 2011;123:18-209
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Ross TD, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011;70:1083-6
   PubMed Web of Science ®Google Scholar
• de Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005;3:1993-7
   PubMed Web of Science ®Google Scholar
• de Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006;107:1916-24
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to Domain 1 of beta 2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015;13:782-7
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Tonello M, et al. Antibodies to Domain 4/5 (Dm4/5) of beta 2-Glycoprotein 1 (beta 2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res 2015;136:161-3
   PubMed Web of Science ®Google Scholar
• Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to β2 glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 2005;3:1231-8
   PubMed Web of Science ®Google Scholar
• Sciascia S, Murru V, Sanna G, et al. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012;10:2512-18
   PubMed Web of Science ®Google Scholar
• Hoxha A, Ruffatti A, Mattia E, et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med 2015;53:1265-70
   PubMed Web of Science ®Google Scholar
• Amengual O, Forastiero R, Sugiura-Ogasawara M, et al. Significance of IgG phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results from the Initial and Validation International multi-centre studies. Ann Rheum Dis 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Sciascia S, Cosseddu D, Montaruli B, et al. Risk scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2011;70:1517-18
   PubMed Web of Science ®Google Scholar
• Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012;64:504-12
   PubMed Web of Science ®Google Scholar
• Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013;52:1397-403
   PubMed Web of Science ®Google Scholar
• Sciascia S, Bertolaccini ML, Roccatello D, et al. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2013;72:142-3
   PubMed Web of Science ®Google Scholar
• Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 2015; Epub ahead of print
   PubMedGoogle Scholar
• Sciascia S, Sanna G, Murru V, et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford) 2015;54:134-8
   PubMed Web of Science ®Google Scholar
• Sciascia S, Cuadrado MJ, Sanna G, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res (Hoboken) 2014;66:1915-20
   PubMed Web of Science ®Google Scholar
• Erkan D, Lockshin MD; APS ACTION members. APS ACTION–AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus 2012;21:695-8
   PubMed Web of Science ®Google Scholar